Hybridomas and monoclonal antibodies for an anticoagulant test
US6538112B2 · kind B2 · utility
0Cited by
28References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 30, 2001 |
| Grant date | Mar 25, 2003 |
| Priority date | — |
| Expiry date | Mar 30, 2021 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70557
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention is a method for diagnosing a patient at risk to thrombocytopenia induced by administration of a GP IIb/IIIa receptor antagonist, which comprises combiningi) a plasma sample of the patient;ii) detectable monoclonal antibody which recognizes induced binding sites formed on the GP IIb/IIIa receptor following association of a fibrinogen receptor antagonist with the GP IIb/IIIa receptor; andiii) GP IIb/IIIa receptor:GP IIb/III receptor antagonist complex,and determining association of the detectable monoclonal antibody with the complex in the presence of the plasma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.